Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

Egypt · Delayed Price · Currency is EGP

5.10

+0.04 (0.79%)

At close: Jun 4, 2026

EGX:RMDA Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, EGX:RMDA stock has a consensus rating of "Buy" and an average price target of E£5.85. The average 1-year stock price forecast is 14.71% higher than the current stock price, while the lowest is E£4.60 (-9.80%) and the highest is E£8.00 (+56.86%).

Price Target: E£5.85 (+14.71%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	E£4.60	E£5.85	E£5.62	E£8.00
Change	-9.80%	+14.71%	+10.20%	+56.86%

Analyst Ratings

The average analyst rating for EGX:RMDA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	6	6	6	5	4	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	1	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	6	6	6

Financial Forecast

Revenue This Year

4.82B

from 4.10B

17.55%

from 4.10B

Revenue Next Year

5.65B

from 4.82B

17.37%

from 4.82B

EPS This Year

0.29

from 0.13

117.07%

from 0.13

EPS Next Year

0.38

from 0.29

29.31%

from 0.29

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.25B	1.48B	1.92B	2.77B	4.10B	4.82B
Revenue Growth	29.81%	19.06%	29.54%	44.03%	47.94%	17.55%
Gross Profit	576.82M	718.67M	904.06M	1.28B	1.98B	2.44B
Gross Margin	46.28%	48.43%	47.03%	46.38%	48.39%	50.70%
Operating Income	274.29M	342.26M	445.76M	725.44M	962.45M	1.36B
Net Income	181.09M	245.68M	244.86M	387.37M	298.46M	585.34M
EPS	-	-	-	-	0.13	0.29
EPS Growth	-	-	-	-	-23.91%	117.07%
Forward PE	10.10	9.25	7.72	10.84	9.19	17.59
Dividend / Share	-	-	0.05	0.04	-	0.06
Free Cash Flow	-7.86M	-108.98M	-381.77M	-552.55M	-834.46M	283.00M
No. Analysts	-	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EGP.

Revenue Forecast

Revenue	2026	2027	2028
High	4.8B
Avg	4.8B
Low	4.8B

Revenue Growth

Revenue Growth	2026	2027	2028
High	17.6%
Avg	17.6%
Low	17.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	0.29
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	117.1%
Low	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.